Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1632 1641 1651
This examiner grants 52% of resolved cases
Examiner Taeyoon Kim operates within Tech Center 1600 and is assigned to Art Unit 1631. Throughout their tenure, they have managed 896 resolved cases, which represents the total number of patent applications that have reached a final resolution. These 896 resolved cases offer a comprehensive view of the examiner's work within Art Unit 1631 and Tech Center 1600.
The records indicate an allowance rate of 51.5 percent, showing the proportion of cases that result in a patent grant. The median days to allowance for these successful applications is 1381. This 1381 days duration serves as a benchmark for the expected length of the prosecution process. The 51.5 percent allowance rate provides a clear expectation for applicants seeking a grant.
A significant factor in this examiner's profile is the interview lift of 52.1 percent. This 52.1 percent lift represents the increase in the likelihood of allowance when an interview is held compared to the baseline rate. Given the typical timeline for successful cases, the 52.1 percent interview lift suggests that direct communication is a highly effective tactic for improving prosecution outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | Non-Final OA | Intellia Therapeutics, Inc. |
| 17611497 | TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 | Final Rejection | Merck Patent GmbH |
| 18039387 | ENGINEERED CELLS FUNCTIONALIZED WITH IMMUNE CHECKPOINT MOLECULES AND USES THEREOF | Final Rejection | The University of North Carolina at Chapel Hill |
| 17602987 | METHODS FOR TREATING INHERITED EYE DEFECTS | Final Rejection | The Regents of the University of California |
| 17496391 | METHODS AND SYSTEMS FOR IMPROVING CELLS FOR USE IN THERAPY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18000865 | DIRECT IN VIVO REPROGRAMMING USING TRANSCRIPTION FACTOR ETV2 GENE FOR ENDOTHELIAL CELL AND VESSEL FORMATION | Non-Final OA | EMORY UNIVERSITY |
| 18514880 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18038630 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18967738 | GENERATION OF LUNG ORGANOIDS FROM PLURIPOTENT STEM CELLS AND USE THEREOF | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 17793506 | METHODS OF TREATING FRAGILE X SYNDROME WITH REELIN | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18357658 | METHODS OF FORMING COMPOSITIONS CONTAINING COLLAGEN | Final Rejection | UNIVERSITY OF SOUTH CAROLINA |
| 18713196 | ESTABLISHMENT OF ERYTHROID PRECURSOR CELL LINE CAPABLE OF CONDITIONAL MATURATION USING GENE OVEREXPRESSION | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18593658 | SYSTEMS AND METHODS FOR PRODUCING PROGENY WITH SELECTIVE TRAITS | Non-Final OA | Brigham Young University |
| 18098994 | Development of decellularized bovine bone graft | Final Rejection | University of Sharjah |
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | Final Rejection | Salk Institute For Biological Studies |
| 17472622 | COMPOSITIONS AND METHODS FOR mRNA DELIVERY | Final Rejection | Translate Bio, Inc. |
| 18769320 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | Non-Final OA | FUJIFILM Cellular Dynamics, Inc. |
| 18002633 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS | Final Rejection | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18041303 | A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE | Final Rejection | Mesoblast International Sárl |
| 17905851 | STEM CELL COMPOSITIONS AND METHODS OF REPAIRING TISSUE | Non-Final OA | SMSBIOTECH, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy